Ensysce Biosciences (ENSC) Expected to Announce Earnings on Friday

Ensysce Biosciences (NASDAQ:ENSC) is expected to announce its earnings results before the market opens on Friday, March 21st. Analysts expect Ensysce Biosciences to post earnings of ($2.74) per share and revenue of $0.25 million for the quarter.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings results on Monday, March 10th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.16). The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%. On average, analysts expect Ensysce Biosciences to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Ensysce Biosciences Stock Down 4.4 %

Shares of NASDAQ ENSC opened at $3.71 on Thursday. The stock’s 50-day simple moving average is $6.01 and its two-hundred day simple moving average is $6.38. Ensysce Biosciences has a twelve month low of $2.12 and a twelve month high of $14.67. The firm has a market capitalization of $5.21 million, a P/E ratio of -0.14 and a beta of 0.64.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.